As 2024 was drawing to a close, OpenAI CEO Sam Altman faced two major problems. He wasn’t getting enough server capacity from Microsoft, his company’s biggest backer, to stay ahead of rivals ...
MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...